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Considerable progress in our understanding  of the basic mechanisms of delayed- 
type hypersensitivity  has  been made in  recent years,  largely as  a  consequence of 
studies in vitro (1, 2). Although most of these studies have approached the problem 
primarily at the phenomenological level, they have established that the immunological 
information necessary for the initiation  of cell-mediated immune reactions in vitro 
is possessed by the small lymphocyte which, upon interaction with specific  antigens 
can influence,  directly or indirectly, a variety of other cells in its environment. 
In order to study the cell-mediated immune response on a quantitative basis, we 
have recently developed a plaque assay which permits determination of the number 
of antigen-sensitive cells within a population of lymphoid cells (3).  The method was 
designed  to detect intrinsic  changes produced in sensitized  lymphocytes as  a  con- 
sequence of activation by antigen, rather than to measure products secreted by such 
cells. The basis for our approach is that unstirnulated lymphocytes generally do not 
support replication of viruses, whereas antigen-activated lymphocytes do so. 
The quantitative  approach  to delayed-hypersensitivity  reactions  in man is 
of interest  at two levels.  Because of their  importance in the rejection  of allo- 
grafts  and  tumors,  and  in  the  course  of some  "autoimmune"  diseases,  there 
is  an  urgent  need  for  quantitative  measurements  in  vitro  of  cell-mediated 
immunity at the clinical level. We can hardly imagine a clinically useful analy- 
sis of an immune response mediated by antibodies  if it could be demonstrated 
only by means of the wheal-and-flare reaction. Yet skin tests are still the prin- 
cipal  measure  of  delayed  hypersensitivity  in  man.  Secondly,  a  method  that 
permits  enumeration  of specifically sensitized  cells is of obvious value for ap- 
proaching an understanding  of the basic mechanisms underlying the delayed- 
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type  hypersensitivity  response.  It  is  perhaps  germane  to  recall  the  insights 
into  the mechanism  of  antibody  formation  which  have been  provided by  the 
Jerne plaque assay. 
In this report we describe the successful application of the virus plaque tech- 
nique  to  the  enumeration  of  antigen-sensitive  cells in  the  peripheral  blood  of 
tuberculin-sensitive human  donors. 
Materials and Methods 
Antigens.--All in vitro work was done with excipient-free, purified protein derivative of 
tuberculin (PPD)1 generously provided by the Ministry of Food, Agriculture, and Fisheries, 
Weybridge, Surrey, England.  Skin tests were carried out with PPD from Parke, Davis and 
Co., Detroit, Mich. 
Peripheral Blood Lymphocytes.-- 
Donors: The blood used in these experiments was  donated  by healthy human  subjects. 
According to their dermal reactivity to tuberculin they were grouped as follows: (a) Donors 
who responded with skin reactions (erythema and induration) greater than 10 mm in diameter 
to intradermal injections of 0.00002 mg of PPD (first test strength). (b) Donors who developed 
delayed skin reactions of similar size only when tested with 0.0001  mg of PPD  (intermediate 
test strength). (c) Donors whose skin reactions to 0.0001 mg of PPD measured less than 6 mm 
in diameter (tuberculin-negative). 
Preparation of peripheral blood lymphocytes: 1 unit of whole blood (470 ml) was drawn by 
the staff of the New York Blood Center into a heparinized sterile plastic bag  (Abbott No. 
4686, Abbott Co., Miami, Fla.). The final concentration of heparin was 4.5 units/ml of blood. 
The bag was immediately attached  to a  Fenwal Leuko-pak  nylon filter  (Fenwal No. 4  C 
2401, Fenwal Laboratories,  Morton  Grove,Ill.), and blood was  allowed to  flow  by gravity 
into another sterile plastic bag (Fenwal Transfer-pak, No. 4 R  2022)  at 37°C over a  period 
of 10-15 mill. To the filtered blood additional preservative-free heparin (10 units/ml, Organon. 
West Orange, N.J.) was added and the blood was drawn into 250 ml plastic syringes. 
The syringes were inverted and the erythrocytes were allowed to sediment at 37°C until 
either 35-400-/0 of plasma had separated or 11/6 hr had elapsed.  The plasma was expelled from 
the syringe into a  125 ml siliconized centrifuge tube and was centrifuged at 200 g for 10 min 
at 4°C. The plasma was  removed and  the cells were washed  in Eagle's minimal essential 
medium (MEM)  (Earle's base) containing 100 units/ml of penicillin and 100 #g/ml of strep- 
tomycin and supplemented with 10% fetal calf serum (FCS)  (Grand Island Biological Co., 
Grand  Island,  N.Y.).  The preparations  were  estimated  to  contain  between  87  and  95% 
lymphocytes. 
Culture of Lymphocytes.--The lymphocyte suspensions  were adjusted to a density of 2 X 
106 viable cells/ml in the culture medium (MEM containing 10% fetal calf serum) and dis- 
tributed in 1 ml volumes into 12  )<  75 mm polypropylene tubes (No. 2063, Falcon Plastics, 
Los Angeles, Calif.). Paired cultures were made in the presence or absence of antigen (PPD, 
5/~g/ml). 
In five experiments, 1/~g/ml of vinblastine (Velban,  Eli Lilly and Co., Indianapolis, Ind.) 
was added to control and PPD-stimulated cultures to inhibit mitosis. In these same experi- 
1  Abbreviations used in this paper: B cell, bone marrow-derived cell; FCS, fetal calf serum; 
MEM, Eagle's minimal essential medium; PFU, plaque-forming units; PPD, purified protein 
derivative of tuberculin; T  cell, thymus-derived or thymus-dependent  cell; VSV,  Vesicular 
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ments, parallel cultures were established under the same conditions for studying mitogenesis 
by means of incorporation of 14C-thymidine. All cultures were incubated vertically at 37°C 
in art atmosphere of 10% COs in humidified air. 
Virus.--Frozen stock of vesicular stomatitis virus (VSV), Indiana strain, was used.  For 
production of virus in quantity confluent monolayers of chicken embryo fibroblasts in MEM 
supplemented with 10% FCS were infected with virus at a multiplicity of 1. Culture superna- 
rants were harvested at 24 hr, centrifuged at 900 g to remove cell debris, frozen in 10% di- 
methyl sulfoxide, and stored at -70°C until used. The fiter, determined after thawing, was 
approximately 10  ° plaque-forming units (PFU)  per milliliter. 
Anti-VSV  Antisera.--Hartley guinea pigs (Hazelton Laboratories, Baltimore, Md.) were 
injected in the footpads and necks with 1 ml containing 109 PFU of VSV (grown in L-cells) 
emulsified with complete Freund adjuvant. At various intervals blood samples were obtained 
and the sera tested for anti-VSV activity by plaque-neutralization tests. When the antibody 
titer was found to be sufficiently high (0.01  ml of serum completely neutralizing 5  X  107 
PFU), the animals were exsanguinated, the sera were pooled, inactivated at 56°C for 30 min, 
and stored at --70°C. 
Preparation  of  Virus-Susceptible  Target Cells.--L-929  mouse fibroblasts were cultivated 
continuously in spinner bottles in suspension medium (Joklik-modified MEM,  Grand  Island 
Biological Co.)  supplemented with 5%  FCS.  For assay of the virus and infectious centers, 
monolayers of target cells were prepared by plating 2.0 X  106 cells in 5 ml of MEM (Earle's 
base) containing 6% FCS  in 60 mm plastic Petri dishes (Falcon Plastics No.  3002)  24 hr 
before use, and by incubating them at 37°C in  10% CO2 in air. At the time of assay the 
L-cells had formed confluent cell monolayers. 
Assay for Virus-Producing Cells.--Mter culture for various periods of time with or without 
PPD, the lymphocytes were washed twice by centrifugafion at 250 g for 10 rain and resus- 
pended in 0.2 ml of culture medium. The cells were infected with VSV at a multiplicity of 50 
and incubated at 37°C for 2 hr to permit virus adsorption and penetration. 
Excess virus was removed by washing the cells twice, and the remaining virus was neutral- 
ized by exposure to 0.01 ml of anti-VSV serum for 1 hr at 4°C. The lymphocytes were then 
washed three times, resuspended in MEM containing 6% FCS, and counted in a Coulter par- 
ticle counter (Coulter Electronics, Hialeah, Fla.) with a  100/z aperture. 
The monolayers  of  L-cells were  drained  and  one  of  several  dilutions of  virus-infected 
lymphocytes was added in 0.2  ml volumes. Next  1 ml of  1% warm  agar  (Ionagar No.  2, 
Oxoid, Colab Laboratories, Inc., Chicago Heights, IlL) in 6% FCS plus MEM, maintained 
at 45°--47°C,  was mixed with the lymphocytes by quickly expelling, withdrawing, and re- 
expelling the entire volume with a warm 1 ml pipette. When this layer of agar had solidified 
(approximately 10 rain) another layer of 1.5 ml of warm agar was added  to provide further 
nutrients. Each cell sample was plated in three dilutions and each dilution plated in duplicate. 
For detecting the possible presence of free virus, samples of  the superuatant, after removal 
of the virus-infected lymphocytes by centrifugation, were routinely plated. 
The plates were incubated at 37°C in 10% CO~ in air for 2 days, then vitally stained with 
1.5 ml of neutral red (1:10000) in Hanks' solution. After 1-3 hr of incubation, the unstained 
plaques of lysed target cells were clearly visible against the red background of stained viable 
cells. The results,  after subtracting plaques from supernatants, were recorded as PFU per 
106 cells plated. 
Determination of Thymidine Incorporation.---Cultures to be tested for mitogenesis received 
0.1 #Ci  of 2-14C-thymidine  (specific  activity 51.8  mCi/m~,  Schwarz  Bio  Research,  Inc., 
Orangeburg, N.Y.) 6 hr before assay. The cells,  after chilling in an ice bath, were retained on 
a 0.22/z membrane filter (GSWPO 25, Millipore Corp., Bedford, Mass.), washed twice with 
cold isotonic saline, and the acid-insoluble fraction was then precipitated on the filter with L.  JIMENEZ,  B.  BLOOM~ :Yl. BLI/~E,  AND  H.  OETTGEN  743 
three 10 ml volumes of 5% trichloracetic acid. The filter containing the precipitate was placed 
under 10 ml of scintillation fluid (containing a mixture of 32 ml Permafluor [Packard Instru- 
ment Company, Downers Grove, Ill.I) in Triton-)[  100  and toluene (1:2) and the disinte- 
grations were counted in a Tracerlab scintillation counter (Traceflab Div., Richmond, Calif.) 
at an efficiency of 75%. 
TABLE  I 
Virus Plaque Formation by Human Lymphocytes Cultured in Medium with or 
without Antigen 
Results of skin test with PPD 
PFU 
per 10e cells 
Medium 
Control  PFD 
A PFU  Average h PFU 
per 10¢ cells  per 10~ cells 
Negative  480  362  -118 
(intermed. test strength)  3300  2,245  --555 
Positive 
(intermed. test strength) 
Positive 
(first test strength) 
750  8,600  7856 
300  4,890  4590 
345  2,700  2355 
90  890  800 
325  3,300  2975 
1095  4,285  3190 
1218  2,767  1549 
412  2,835  2423 
3780  12,868  9088 
2198  6,075  3892 
3768  6,057  2289 
2295  4,630  2335 
-4-SE 
--337  ±  218 
3627  q-  893 
3596  .4-  1144 
RESULTS 
Purified peripheral blood lymphocytes from the three groups of donors were 
cultured in the presence or absence of antigen (PPD) in 14 experiments. After 
various periods of time the cells were removed, infected with VSV, and plated 
in the plaque assay to permit enumeration of virus-producing cells.  The in- 
dividual results  of both  control and  PPD-stimulated  cultures  of  14  donors 
after 3 days are presented in Table I. While the background of virus-producing 
cells in control medium varied, there was a significant increase in the number of 
plaque-forming cells in the PPD-stimulated cultures of lymphocytes obtained 
from hypersensitive donors in every experiment. The lymphocytes of tubercu- 
lin-negative donors in two control experiments failed to produce an increase 744  LYMPIIOCYTES  IN  DELAYED-HYPERSENSITIVE  HUMAN  DONORS 
in  the number  of plaques  above  control levels after cultivation with PPD. 
The  difference between  the  numbers  of PFU  in  cultures  with and  without 
antigen (APFU)  is assumed to represent the number of antigen-sensitive cells 
in  the  population.  Interestingly,  lymphocytes  obtained  from  donors  with 
positive skin reactions to intermediate strength PPD  (0.0001 mg)  or to first 
test strength (0.00002 mg) gave quite similar values for antigen-sensitive cells 
in this assay. The mean maximum number of antigen-reactive cells observed 
on day 3 was 3.6 ~  1.0/1000  cells plated (Table I). 
In previous studies of the rate of activation of sensitized guinea pig lymph 
node lymphocytes by PPD  it was found that the increase was linear over a 
4 day period (3). Inhibition of cell division by vinblastine, colchicine,  or thy- 
midine blockade failed to  lower significantly the number  of plaque-forming 
cells observed after 2 days of stimulation. Unfortunately, interpretation of the 
data in these studies obtained after 48  hr of culture was  complicated by the 
low viability in the cell cultures. The better survival of human lymphocytes 
in  culture  afforded a  superior system for analyzing  the  kinetics  of  plaque 
formation. 
In five of these experiments lymphocytes from hypersensitive donors were 
cultured with PPD  in the presence or absence  of the mitotic inhibitor vin- 
blastine (Velban) before virus infection and assay. Parallel cultures of the same 
cells were analyzed on days 24  by means of both the virus plaque assay and 
the determination of 14C-thymidine  incorporation into DNA  as  an index  of 
mitotic activity. The results are shown in Fig. 1. The increase in the number of 
plaque-forming lymphocytes after  antigenic  stimulation  was  approximately 
linear, as was the case with guinea pig lymph node cells. Further, the presence 
of the mitotic inhibitor had no effect on the response. (Fig. 1 A). 
In contrast, the increase in thymidine incorporation after antigenic stimula- 
tion (Fig. 1 B) was nonlinear and possibly exponential. It is clearly evident that 
vinblastine was  effective in  totally suppressing  antigen-induced mitotic ac- 
tivity under the conditions of the experiment. Indeed, the thymidine incorpora- 
tion by  the antigen-stimulated cultures was less than that of the control cultures, 
perhaps indicating that many cells in the antigen-stimulated culture entered 
the mitotic cycle and were then killed by the effects of the mitotic inhibitor. 
DISCUSSION 
Two  types of  in  vitro  systems have  been  used  previously to  assay cell- 
mediated immune responses. The first measures the ability of antigen-activated 
lymphocytes to exert a direct cytotoxic effect on a variety of target cells (4, 5). 
The  second  type  depends  upon  detection  of  soluble products  produced  by 
antigen-stimulated lymphocytes (1). While both these approaches hold promise, 
they have not yet provided sensitive and reproducible in vitro assays for cell- 
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The virus plaque assay used here depends upon a change in sensitized lympho- 
cytes, brought  about by specific antigens, which  enables them to support the 
replication  of  RNA  viruses.  Studies  in  several  laboratories  had  previously 
shown  that,  while  normal  lymphocytes  were  essentially unable  to  replicate 
viruses,  lymphocytes activated by phytohemagglutinin  produced  substantial 
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FIG. 1 A. Effect of vinblastine on the increase in antigen-sensitive ceils (ApFU) detected 
by the virus plaque assay after PPD stimulation. Q--Q indicate the average for five donors 
cultured in the absence of mitotic inhibitor; O--O indicate the results of the same donors' 
cells cultured in the presence of vinblastine (1 ttg/ml). 
FIG. 1 B.  Effect of vinblastine on the incorporation of ltC-thymidine into DNA following 
PPD stimulation. O--Q indicate the average increase in incorporation for paired cultures 
from the same five donors as above in the absence of mitotic inhibitor; O--O indicate the 
average results of the same donors' cells cultured in the presence of vinblastine (1 btg/ml). 
yields (6-8). Our own work indicated that this is also the case when sensitized 
lymphocytes are activated by antigen. Lymphocytes from tuberculin-sensitive 
guinea  pigs  stimulated  by  PPD  allowed  replication  of  two  different  RNA 
viruses, Newcastle disease virus and vesicular stomatitis virus,  to  essentially 
the same degree, indicating that the number of virus plaques observed reflects 
a property of the activated lymphocytes and not of the virus used (3). 
The correlation of the assay with delayed-type hypersensitivity was demon- 
strated by two types of control experiments. Lymphocytes from normal, non- 
sensitized animals produced no increase in the number of plaques after culture 746  LYMPItOCYTES  IN  DELAYED-HYPERSENSITIVE  HUMAN  DONORS 
with  PPD.  Furthermore,  lymphocytes from guinea pigs  that  had  been  im- 
munized with PPD  adsorbed onto alumina to produce circulating antibodies 
and not possessing delayed-type hypersensitivity, did not produce an increased 
number of viral plaque-forming cells upon culture in vitro with PPD. 
As in the Jerne assay for antibody-producing cells, there is a background of 
virus plaques produced by the cells of nonstimulated control cultures. When this 
background is subtracted from the number of plaques observed after antigenic 
stimulation, the increment in plaque-forming cells  (APFU)  has been taken to 
represent the number of antigen-sensitive cells in the population. 
The present results indicate that the virus plaque assay can be successfully 
applied to the study in vitro of delayed-type hypersensitivity in man. In the 
case of most highly skin-reactive indivuduals who were positive to first test 
strength  PPD,  we  observed  a  linear increase  of virus-producing  cells,  as  in 
the guinea pig,  rising to a maximum of approximately 6/1000 cells on the 4th 
day of culture with PPD  (Fig.  1 A). This figure is somewhat lower than the 
maximal number of antigen-sensitive cells detected in lymph node cell popu- 
lations  of  exquisitely  sensitive  guinea  pigs  (approximately  20/1000  cells) 
but interestingly it is of the same order of magnitude as that detected in mixed 
cultures of lymphocytes from two normal, unrelated donors are cocultivated 
(9,  10). That donors with skin reactions to intermediate or to first strength 
PPD  had  approximately equal numbers  of virus  plaque-producing  lympho- 
cytes suggests that differences in skin reactivity could result from secondary 
events at the test site rather than from differences in the numbers of committed 
lymphocytes. 
Perhaps  the most surprising aspect of the results is the apparent linearity 
of the increase in APFU as the cells are cultured with antigen over a 4  day 
period.  From other studies we might have expected an exponential increase. 
In careful cinemicrographic studies of blast  cell  transformation of sensitized 
human peripheral lymphocytes by antigens, Marshall et al.  observed an ex- 
ponential increase in the number of transformed cells after a  latent period of 
about 48 hr (11).  Numerous studies of the kinetics of production of antibody 
plaque-forming cells in the Jerne assay have shown, both in vivo and in vitro, 
that  the production  of  antibody-forming cells  generally follows  exponential 
kinetics (12-14). 
There  are at least two plausible explanations for our findings. First,  it  is 
possible that the plaque-forming cells in this assay are in fact  dividing, but 
because of imperfect culture conditions, as some cells divide others may die; 
thus,  the linear relationship observed would be merely fortuitous.  Secondly, 
we may be detecting a  cell which is distinct from the cell measured in blast 
cell transformation or in antibody formation by virtue of its being nondividing 
under the conditions of our experiments. We have tested the former possibility 
by using vinblastine, an irreversible inhibitor of mitosis (15). The results shown L.  JIMENEZ,  B.  BLOOM,  M.  BLUME,  AND  H.  OETTGEN  747 
in Figure 1 A clearly indicate a linear increase in the number of viral plaque- 
forming cells,  which is  unaffected by the  presence  of  the  mitotic inhibitor. 
In previous work with guinea pigs,  thymidine blockade and colchicine were 
employed in addition to stop mitosis; the results were essentially the same (3). 
That vinblastine under the conditions employed was effective in inhibiting 
mitosis is demonstrated by the results shown in Figure 1 B. Blastogenesis in 
parallel cultures, as detected by thymidine incorporation, was abrogated when 
vinblastine was added. Preliminary experiments have indicated that two cells 
are involved in the activation of lymphocytes by antigen to produce  virus, 
and the slow  increase in plaque-forming cells  probably reflects the time re- 
quired for cell  interaction.  ~ We are  thus led to  the conclusion that  the cell 
measured by the virus plaque assay is essentially a  nondividing cell, at least 
during the period of the test, and that it is likely to be distinct from the anti- 
body-producing cell or the blast cell. However, it is clear that it must be de- 
rived from dividing precursors and it cannot be excluded that, at a later stage 
or  in  a  different anatomic compartment,  it might become again  a  dividing 
cell. 
It is our view that the antigen-sensitive cell in this system may well be the 
effector cell which mediates delayed-type hypersensitivity reactions in vivo. 
There are at least five lines of evidence indicating that this effector cell does 
not divide: (a) There is little or no indication that significant numbers of lymph- 
ocytes proliferate at the reaction site (16).  (b) Many delayed-type reactions 
in vivo reach their maximum at 24-30  hr,  declining after 36-48  hr. This is 
in contrast to the mitogenic response of human lymphocytes following antigenic 
stimulation in vitro which does not begin until approximately 48 hr and pro- 
ceeds to a maximum in 6-7 days, long after in vivo reactions would have dis~ 
appeared. (c) In passive transfer experiments in the guinea pig (17), sensitized 
lymphocytes treated with low doses of mitomycin C, under conditions where 
cell division would be blocked, were perfectly capable of effecting transfer of 
contact and tuberculin hypersensitivity reactions.  (d) While the induction of 
cell-mediated ilnlnunity to Listeria  monocytogenes infection in  mice requires 
division, once cellular immunity is acquired it is completely resistant to treat- 
ment  with  vinblastine  in  vivo  (18).  (e)The  delayed-type hypersensitivity 
response  is  much  less  sensitive  to  radiation  than  antibody formation  (19). 
It thus appears likely that the effector cell mediates the delayed-hypersensi- 
tivity reaction directly without dividing, 
On the basis of work done in many laboratories, we may summarize the char- 
acteristics  of  the  cell  involved  in  mediating  delayed-type hypersensitivity 
reaction as follows: (a) It is a  thymus-derived or thymus-dependent (T)  cell 
(20-23).  (b)With  respect  to  hapten-protein  conjugates  this  cell  is  believed 
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to have specificity primarily for "carrier" antigenic determinants in contrast 
to antibody-forming cells which are primarily hapten-specific (24, 25).  (c) The 
cell is not believed to be engaged to any significant degree in secretion of anti- 
body. (d) It is a radiation-resistant, nondividing cell (see above). 
It seems to us that the cell with these characteristics might have a broader 
immunological function than involvement solely in the  effector process  in de- 
layed-type hypersensitivity reactions. Present information on the mechanism 
of production  of antibodies  suggests  that  cell  cooperation between  two cell 
types is  required  in at least some systems. One cell type, a bone marrow-de- 
rived or B cell, actually synthesizes and secretes the antibody molecules, which 
are found primarily to have specificity for haptenic determinants. However, 
before the B  cells  can differentiate and produce antibodies,  interaction with 
a  thymus-dependent cell (T cell) which is responsible for antigen recognition 
is required (26,  27).  This T  cell has been shown to be radiation-resistant and, 
presumably, nondividing (28).  Further,  in  the  secondary antibody response, 
it primarily has carrier specificity (29-31). 
In our view the characteristics of the effector cell in delayed-type hypersen- 
sitivity cannot be distinguished from those of the thymus-derived helper cell 
which carries immunological memory in antibody formation and may be the 
same cell. Upon being engaged by carrier determinants on antigen molecules, 
this cell may mediate the delayed-type response directly or by means of the 
various soluble products which it releases such as migration-inhibitory factor, 
chemotactic factor,  lymphotoxin,  blastogenic factor,  etc.  It  is  tempting  to 
speculate that one factor elaborated by this cell may activate those bone mar- 
row-derived B  cells  which have been engaged by haptenic determinants,  to 
proliferate and to differentiate into plasma cells and produce antibodies. An 
intimate relationship between delayed hypersensitivity and antibody formation 
has certainly been suggested previously by several authors (32-35).  The hy- 
pothesis, as presented here, has the virtues of serving to unify the mechanisms 
of the two immune responses as well as being amenable to direct experimental 
testing. 
SUMMARY 
The virus plaque assay has been successfully employed to enumerate antigen- 
sensitive cells  in the peripheral blood lymphocyte populations of tuberculin- 
hypersensitive human donors. The method is based on the finding that, while 
resting lymphocytes are unable to produce a variety of viruses upon infection, 
lymphocytes activated by specific antigens become capable of virus replication. 
The average number of antigen-sensitive cells detected in cell populations from 
donors reacting to first test strength or intermediate test strength tuberculin 
was approximately  3.6/1000 lymphocytes, and the averages for both groups were 
similar. 
Studies on the kinetics of appearance of these virus plaque-forming cells and L.  J'IMENEZ~  B.  :BLOOM, :~.  BLUME~ AND  tt.  OETTGEN  749 
on the effects of the mitotic inhibitor, vinblastine, indicate that the activation 
of these  antigen-sensitive  cells is a  linear process and  that  the cells must be 
nondividing  cells during  this process. These qualities  contrast markedly with 
those  described for the  mitogenic response and  the  antibody-producing  cells 
which  require  cell division  and increase exponentially.  On  the basis  of these 
experiments it is suggested that the antigen-sensitive cell measured in the virus 
plaque assay is the effector cell in delayed-type hypersensitivity reactions and, 
in addition,  may be one of the cells critically involved in antibody formation. 
We are pleased to acknowledge the excellent technical assistance of Mrs. Gisela Sorg, 
Mrs. Judith  Gaffney, Mrs. Gail Jimenez, and Mrs. Deanna N. Howe in these experiments. 
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